Sonoma Pharmaceuticals (SNOA) Total Debt Growth (3y) (2014 - 2026)
Sonoma Pharmaceuticals (SNOA) Total Debt Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | 15.43% |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | -7.08% |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 11.33% |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | -3.67% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -10.43% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | -13.72% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 92.83% |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | -22.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.52% |
| Mar 31, 2026 | -19.84% |
| Sep 30, 2025 | -38.77% |
| Jun 30, 2025 | -33.56% |
| Mar 31, 2025 | -31.62% |
| Sep 30, 2024 | -48.11% |
| Jun 30, 2024 | -46.20% |
| Mar 31, 2024 | -44.66% |
| Dec 31, 2023 | -67.74% |
| Sep 30, 2023 | -49.79% |
| Jun 30, 2023 | -42.40% |
| Mar 31, 2023 | -3.59% |
| Sep 30, 2022 | 32.04% |
| Jun 30, 2022 | 30.97% |
| Mar 31, 2022 | 27.24% |
| Dec 31, 2021 | 198.82% |
| Sep 30, 2021 | 81.00% |
| Jun 30, 2021 | 80.44% |
| Mar 31, 2021 | 93.76% |
| Dec 31, 2020 | 203.20% |